INTRODUCTION {#s1}
============

Primary central nervous system (CNS) lymphoma (PCNSL) is an extranodal non-Hodgkin lymphoma (NHL) confined to the CNS, mostly diffuse large B-cell lymphoma (DLBCL) \[[@R1]\]. Currently, the International Extranodal Lymphoma Study Group (IELSG) and Memorial Sloan Kettering Cancer Center (MSKCC) prognostic scoring systems are the best available clinical tools to risk-stratify patients with PCNSL \[[@R2], [@R3]\]. However, these prognostic scores do not take into account underlying tumor biological factors, such as tumor microenvironment of PCNSL. Several biomarkers for PCNSL have been suggested, including multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4), B-cell lymphoma-6 (BCL-6) and CD68, but their major limitation is that it is difficult to use those biomarkers as a potential therapeutic target \[[@R4]--[@R6]\]. Therefore, discovering a novel biomarker that supplements IELSG and MSKCC prognostic scoring system and that can be used as a therapeutic target is desperately needed to improve prognostication and survival of patients with PCNSL.

Tumor microenvironment per se is important for PCNSL development and progression as well as other malignancies \[[@R7]\]. This is also supported by the study that showed characteristic infiltration by tumor infiltrating lymphocytes in perivascular microenvironment of PCNSL, which was associated with survival \[[@R8]\]. Albeit the immunological role of T-cell infiltration in PCNSL is unclear, emerging data are suggesting that tumors have developed evasion mechanisms that exploit immune checkpoints to overcome antitumor immunity \[[@R9]\].

The immune checkpoint molecule programmed cell death 1 (PD-1) and its ligands PD-L1 and PD-L2 have been shown to play key roles in inhibiting T cell activity in the tumor microenvironment, not only in solid cancers but also in hematologic malignancies \[[@R10]\]. PD-1 and its ligands have been highlighted because their blockade showed outstanding clinical responses in advanced hematologic malignancies \[[@R11]\].

Importantly, PCNSL exhibited frequent 9p24.1/PD-L1/PD-L2 copy number alterations \[[@R9]\] and even PD-1 blockade demonstrated clinical activity in relapsed/refractory PCNSL \[[@R12]\], although only small number of patients were evaluated. Based on these findings, we sought to evaluate PD-1, PD-L1, and PD-L2 expressions in immunocompetent PCNSL patients at diagnosis, as well as their prognostic implication.

RESULTS {#s2}
=======

Patients' characteristics {#s2_1}
-------------------------

Baseline patient characteristics according to PD-1, PD-L1, and PD-L2 expression levels are summarized in Table [1](#T1){ref-type="table"}. The median follow-up duration for all patients was 20.2 (range, 2.2--128.5) months, and the median follow-up duration for surviving patients was 31.9 (range, 2.4--128.5) months. Serum Epstein-Barr virus (EBV) DNA was detected in 16 (21.1%) patients (median 9,200 \[range 1,944-88,000\] copies/mL blood).

###### Baseline characteristics of all patients and subgroups according to the levels of PD-1, PD-L1, and PD-L2 expression

  Clinical features, *n* (%)   Entire cohort       Subgroups                                                                                                                            
  ---------------------------- ------------------- ------------------- ----------------- ------- ------------------- ------------------ ------- ------------------- ------------------- -------
  Median age, year             57 (33-79)          56 (33-79)          59 (34-68)                56 (33-79)          59 (34-64)                 58 (36-79)          56 (33-74)          
  Age \>60                     30 (39.5)           28 (40.0)           2 (33.3)          0.556   28 (42.4)           2 (20.0)           0.158   27 (61.4)           19 (59.4)           0.524
  Male gender                  39 (51.3)           36 (51.4)           3 (50.0)          0.637   35 (53.0)           4 (40.0)           0.334   23 (52.3)           16 (50.0)           0.514
  ECOG PS ≥2                   35 (46.1)           34 (48.6)           1 (16.7)          0.209   29 (43.9)           6 (60.0)           0.271   17 (38.6)           18 (56.3)           0.099
  Elevated serum LDH           34 (44.7)           33 (47.1)           1 (16.7)          0.216   29 (43.9)           5 (50.0)           0.489   20 (45.5)           14 (43.8)           0.535
  Deep lesion                  51 (67.1)           47 (67.1)           4 (66.7)          0.649   43 (65.2)           8 (80.0)           0.293   27 (61.4)           24 (75.0)           0.158
  Elevated CSF protein         30/66 (39.4)        28/61 (40.0)        2/5 (33.3)        0.587   27/57 (40.9)        3/9 (30.0)         0.339   18/39 (40.9)        12/27 (37.5)        0.546
  Positive serum EBV           16 (21.1)           14 (20.0)           2 (33.3)          0.371   14 (21.2)           2 (20.0)           0.648   11 (25.0)           5 (15.6)            0.242
  Histology, DLBCL/PTCL        75(98.7)/1(1.3)     69(98.6)/1(1.4)     6(100.0)/0(0.0)   0.921   65(98.5)/1(1.5)     10(100.0)/0(0.0)   0.868   43(97.7)/1(2.3)     32(100.0)/0(0.0)    0.579
  IELSG                                                                                  0.257                                          0.507                                           0.097
   Low (0-1)                   12 (15.8)           10 (14.3)           2 (33.3)                  10 (15.2)           2 (20.0)                   8 (18.2)            4 (12.5)            
   Intermediate (2-3)          46 (60.5)           43 (61.4)           3 (50.0)                  41 (62.1)           5 (50.0)                   29 (65.9)           17 (53.1)           
   High (4-5)                  8 (10.5)            8 (11.4)            0 (0.0)                   6 (9.1)             2 (20.0)                   2 (4.5)             6 (18.8)            
   Missing                     10 (13.2)           9 (12.9)            1 (16.7)                  9 (13.6)            1 (10.0)                   5 (11.4)            5 (15.6)            
  MSKCC                                                                                  0.180                                          0.433                                           0.208
   Low (0)                     15 (19.7)           13 (18.6)           2 (33.3)                  13 (19.7)           2 (20.0)                   9 (20.5)            6 (18.8)            
   Intermediate (1)            32 (42.1)           29 (41.4)           3 (50.0)                  27 (40.9)           5 (50.0)                   21 (47.7)           11 (34.4)           
   High (2)                    29 (38.2)           28 (40.0)           1 (16.7)                  26 (39.4)           3 (30.0)                   14 (31.8)           15 (46.9)           
  Initial treatment MVD/MVP    41(53.9)/35(46.1)   37(52.9)/33(47.1)   4(66.7)/2(33.3)   0.416   40(60.6)/26(39.4)   1(10.0)/9(90.0)    0.003   25(56.8)/19(43.2)   16(50.0)/16(50.0)   0.361
  Non-CR1                      37 (48.7)           34 (48.6)           3 (50.0)          0.389   31 (47.0)           6 (60.0)           0.562   22 (50.0)           15 (46.9)           0.380
  Upfront ASCT                 16 (21.1)           15 (21.4)           1 (16.7)          0.629   13 (19.7)           3 (30.0)           0.352   9 (20.5)            7 (21.9)            0.550
  Salvage ASCT                 10 (13.2)           8 (11.4)            2 (33.3)          0.176   9 (13.6)            1 (10.0)           0.609   7 (15.9)            3 (9.4)             0.318
  Consolidation WBRT           12 (15.8)           8 (11.4)            4 (66.7)          0.657   5 (7.6)             7 (70.0)           0.495   7 (15.9)            5 (15.6)            0.384
  Salvage WBRT                 14 (18.4)           13 (18.6)           1 (16.7)          0.696   12 (18.2)           2 (20.0)           0.590   9 (20.5)            5 (15.6)            0.411

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; DLBCL, diffuse large B-cell lymphoma; PTCL, peripheral T-cell lymphoma; IELSG, International Extranodal Lymphoma Study Group; MSKCC, Memorial Sloan Kettering Cancer Center; MVD, methotrexate, vincristine and dexamethasone; MVP, methotrexate, vincristine, procarbazine and dexamethasone; CR1, complete response after first two cycles of chemotherapy; ASCT, autologous stem-cell transplantation; WBRT, whole-brain radiotherapy.

All the patients received high-dose-methotrexate (HD-MTX)-based chemotherapy as an initial treatment and there were no significant differences in survival according to the initial HD-MTX-based chemotherapy regimens patients received. Sixteen (21.1%) patients received consolidative upfront autologous stem-cell transplantation (ASCT) after a median of 4 cycles (range 2--4) of HD-MTX-based chemotherapy. Ten (16.7%) patients received salvage ASCT. Busulfan plus thiotepa conditioning regimen was used for upfront or salvage ASCT. Twelve (15.8%) patients received consolidation whole-brain radiotherapy (WBRT, median 40.5 \[range 25.2--45.0\] Gy), and 14 (18.4%) patients underwent salvage WBRT (median 41.4 \[range 36.0--54.0\] Gy).

Patients did not reach median Overall survival (OS), and the median progression-free survival (PFS) was 18.4 months (95% CI, 9.9--26.8). The two-year OS and PFS rates were 76.3% and 45.4%, respectively.

Immunohistochemical PD-1, PD-L1 and PD-L2 expression {#s2_2}
----------------------------------------------------

Overall, the median PD-1 positive cells/high power field (HPF) was 0 (range, 0--240). Among 76 patients, 41 (53.9%) patients did not show PD-1 positive cells/HPF. However, remaining 35 (46.1%) patients expressed at least one PD-1 positive cells/HPF. The median positive cells/HPF was 10 (range, 0--300) for PD-L1 and 70 (range, 0--300) for PD-L2. Twenty-two (28.9%) and 12 (15.8%) patients did not express PD-L1 and PD-L2, respectively. Remaining 54 (71.1%) and 64 (84.2%) patients expressed at least one PD-L1 and PD-L2 positive cells/HPF, respectively. We stratified patients into high or low PD-1, PD-L1, and PD-L2 expression groups according to the area under curve (AUC)-based cut-off values. Six (7.9%) patients were stratified into the high PD-1 expression group. Ten (13.2%) and 32 (42.1%) patients were stratified into the high PD-L1 and high PD-L2 expression groups, respectively. Representative immunohistochemical stains of PD-1 (Figure [1b](#F1){ref-type="fig"}), PD-L1 (Figure [1c](#F1){ref-type="fig"}), and PD-L2 (Figure [1d](#F1){ref-type="fig"}) are shown in Figure [1](#F1){ref-type="fig"} with unstained control (Figure [1a](#F1){ref-type="fig"}).

![Representative immunohistochemical stains in formalin-fixed and paraffin-embedded samples\
Negative control **(a)**, high PD-1 expression **(b)**, PD-L1 **(c)**, and PD-L2 **(d)** with anti-PD-1 antibody (NAT105, a and b), anti-PD-L1 antibody (ab58810, c), and anti-PD-L2 antibody (MIH18, d). Magnification, ×400.](oncotarget-08-87317-g001){#F1}

Prognostic factors for survival {#s2_3}
-------------------------------

On univariate analysis, age \> 60 years and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2, MSKCC prognostic scoring, IELSG prognostic scoring, and high PD-1 expression level were associated with inferior OS. MSKCC prognostic scoring, patients who did not achieve complete response at initial interim response (non-CR1), patient who did not receive upfront ASCT, and high PD-1 level were associated with inferior PFS also in univariate analysis. On multivariate analysis, high PD-1 (hazard ratio (HR): 4.95, 95% confidence interval (CI): 1.54--15.86, *P =* 0.007) and MSKCC prognostic scoring (HR: 2.56, 95% CI: 1.17-5.64, *P =* 0.019) were independently associated with inferior OS. High PD-1 also remained an independent prognostic factor for inferior PFS, (HR 2.73, 95% CI: 1.12-6.69, *P =* 0.028) as did MSKCC prognostic scoring (HR: 1.56, 95% CI: 1.09-2.45, *P =* 0.041) on multivariate analysis. However, PD-L1 and PD-L2 expression levels were not prognostic in our cohort (Table [2](#T2){ref-type="table"}).

###### Univariate and multivariate analyses for overall survival (OS) and progression-free survival (PFS)

  Clinical features      Univariate analysis   Multivariate analysis                                                  
  ---------------------- --------------------- ----------------------- ------------------- ------- ------------------ -------
  Age \>60 years         0.038                 0.159                                                                  
  Male gender            0.140                 0.707                                                                  
  ECOG PS≥2              0.047                 0.353                                                                  
  Elevated LDH           0.209                 0.103                                                                  
  Deep brain lesion      0.696                 0.361                                                                  
  Elevated CSF protein   0.074                 0.064                                                                  
  Positive serum EBV     0.148                 0.173                                                                  
  Non-CR1                0.791                 0.005                                                                  
  Non-upfront ASCT       0.238                 0.040                                                                  
  MSKCC scoring          0.029                 0.046                   2.56 (1.17-5.64)    0.019   1.56 (1.09-2.45)   0.041
  IELSG scoring          0.036                 0.487                                                                  
  PD-1 ≥70 cells/HPF     0.018                 0.043                   4.95 (1.54-15.86)   0.007   2.73 (1.12-6.69)   0.028
  PD-L1 ≥100 cells/HPF   0.764                 0.793                                                                  
  PD-L2 ≥100 cells/HPF   0.306                 0.940                                                                  

OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; CR1, complete response after first two cycles of chemotherapy; ASCT, autologous stem-cell transplantation; HPF, high power field; MSKCC, Memorial Sloan Kettering Cancer Center; IELSG, International Extranodal Lymphoma Study Group.

Survival according to the expression levels of PD-1, PD-L1, and PD-L2 {#s2_4}
---------------------------------------------------------------------

Patients with high expression of PD-1 showed significantly shorter 2-year OS and PFS of 33.3% and 0.0%, in comparison to 81.2% and 50.5% for those with low expression of PD-1 (*P =* 0.008 for OS; Figure [2a](#F2){ref-type="fig"}, and P *=* 0.037 for PFS; Figure [2b](#F2){ref-type="fig"}), respectively.

![The overall survival (OS) and progression-free survival (PFS) according to the level of PD-1 expression (**a** for OS and **b** for PFS), PD-L1 expression (**c** for OS and **d** for PFS), and PD-L2 expression (**e** for OS and **f** for PFS).](oncotarget-08-87317-g002){#F2}

Regarding PD-1 ligands, there were no differences in survival according to the levels of PD-L1 and PD-L2 expression (Figure [2c](#F2){ref-type="fig"}-[2d](#F2){ref-type="fig"} for PD-L1 and Figure [2e](#F2){ref-type="fig"}-[2f](#F2){ref-type="fig"} for PD-L2, respectively). Two-year survival rates of patients according to the PD-1, PD-L1, and PD-L2 expression status are provided in Table [3](#T3){ref-type="table"} and associations of PD-1, PD-L1, and PD-L2 expression levels with survival are summarized in Table [4](#T4){ref-type="table"}.

###### Two-year overall survival of patients according to their PD-1, PD-L1, and PD-L2 expression status

  Clinical features, *n*     Entire cohort   Two-year overall survival (%)                                                           
  -------------------------- --------------- ------------------------------- ------ --------- ------- ------- ------- ------- ------ -------
  Age                                                                                                                                
   ≤60                       46              88.7                            50.0   0.028     84.5    85.7    0.764   88.6    76.0   0.405
   \>60                      30              66.2                            0.0    0.134     61.9    0.0     0.737   66.3    28.6   0.409
  Gender                                                                                                                             
   Male                      37              88.0                            33.3   0.008     78.2    100.0   0.274   83.3    82.4   0.718
   Female                    39              74.0                            33.3   0.231     73.9    33.3    0.344   81.5    36.0   0.111
  ECOG PS                                                                                                                            
   \<2                       41              91.6                            40.0   0.004     82.0    100.0   0.377   92.4    66.1   0.070
   ≥2                        35              65.9                            0.0    0.199     66.2    50.0    0.981   57.9    65.9   0.572
  Serum LDH                                                                                                                          
   Not elevated              42              71.6                            40.0   0.162     66.9    66.7    0.754   75.2    50.6   0.243
   Elevated                  34              89.9                            0.0    0.024     87.5    80.0    0.949   87.7    83.6   0.813
  Serum EBV DNA load                                                                                                                 
   Not detected              60              81.7                            50.0   0.143     80.4    71.4    0.086   85.4    67.4   0.248
   Detected                  16              77.4                            0.0    0.108     58.0    100.0   0.354   64.6    60.0   0.756
  Tumor location                                                                                                                     
   Non-deep lesion           25              77.6                            50.0   0.469     70.6    100.0   0.338   77.4    71.4   0.530
   Deep lesion               51              81.4                            0.0    0.009     77.9    62.5    0.730   83.1    65.5   0.368
  CSF protein                                                                                                                        
   Not elevated              36              91.8                            33.3   0.001     83.5    100.0   0.320   83.3    90.9   0.569
   Elevated                  30              64.3                            50.0   0.673     72.3    33.3    0.440   76.6    30.3   0.249
   Not available             10              85.7                            0.0    0.155     68.6    100.0   0.558   0.0     60.0   0.295
  IELSG                                                                                                                              
   Low (0-1)                 12              77.1                            50.0   0.426     65.6    100.0   0.377   75.0    66.7   0.743
   Intermediate (2-3)        46              88.9                            33.3   0.015     82.4    100.0   0.315   83.2    85.7   0.898
   High (4-5)                8               28.1                            N/A    N/A       66.7    0.0     0.623   50.0    31.3   0.275
   Missing                   10              85.7                            0.0    0.155     100.0   68.6    0.558   100.0   60.0   0.295
  MSKCC                                                                                                                              
   Low (1)                   15              100.0                           0.0    \<0.001   84.6    100.0   0.571   100.0   66.7   0.070
   Intermediate (2)          32              83.9                            66.7   0.531     77.6    100.0   0.321   81.5    80.0   0.858
   High (3)                  29              62.1                            0.0    0.333     67.2    0.0     0.235   65.2    33.7   0.468
  Initial interim response                                                                                                           
   CR1                       39              83.6                            25.0   0.007     77.6    66.7    0.839   80.8    65.6   0.605
   Non-CR1                   37              77.0                            50.0   0.474     73.8    75.0    0.896   80.9    64.5   0.282
  Upfront ASCT                                                                                                                       
   Yes                       16              100.0                           0.0    \<0.001   92.3    100.0   0.395   100.0   85.7   0.738
   No                        60              74.4                            40.0   0.160     53.3    71.8    0.780   76.2    54.5   0.307
  Consolidation WBRT                                                                                                                 
   Yes                       12              66.7                            50.0   0.707     70.4    0.0     0.089   79.1    0.0    0.021
   No                        64              85.4                            0.0    \<0.001   78.0    100.0   0.159   81.9    80.9   0.962

ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; EBV, Epstein-Barr virus; CSF, cerebrospinal fluid; IELSG, International Extranodal Lymphoma Study Group; MSKCC, Memorial Sloan Kettering Cancer Center; CR1, complete response after first two cycles of chemotherapy; ASCT, autologous stem-cell transplantation; WBRT, whole-brain radiotherapy; N/A, not available.

###### Association of PD-1, PD-L1, and PD-L2 expression with survival

  Clinical features   Total patients(*n*)   Deaths(*n*)   Median OS(95% CI)   *P*     Progression(*n*)   Median PFS(95% CI)   *P*
  ------------------- --------------------- ------------- ------------------- ------- ------------------ -------------------- -------
  PD-1, cells/HPF                                                             0.008                                           0.037
   \<70               70                    12            Not reached                 34                 24.7 (9.8-39.5)      
   ≥70                6                     4             15.8 (11.7-19.9)            6                  10.4 (3.3-17.5)      
  PD-L1, cells/HPF                                                            0.814                                           0.895
   \<100              66                    14            Not reached                 34                 17.9 (6.9-28.8)      
   ≥100               10                    2             Not reached                 6                  23.4 (13.1-33.8)     
  PD-L2, cells/HPF                                                            0.310                                           0.953
   \<100              44                    8             Not reached                 24                 23.4 (12.8-33.9)     
   ≥100               32                    8             Not reached                 16                 17.1 (13.9-20.3)     

OS, overall survival; PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; HPF, high power field.

Subgroup analysis of patients without upfront ASCT according to PD-1 expression level {#s2_5}
-------------------------------------------------------------------------------------

As high PD-1 expression was independently associated with inferior survival in our whole patients, we performed subgroup analysis in patients who did not undergo upfront ASCT according to the level of PD-1 expression to consider further confounding variables. In 60 (78.9%) patients who did not undergo upfront ASCT, high PD-1 expression was observed in 5 (8.3%) patients and they tended to associate with inferior survival (Figure [3a](#F3){ref-type="fig"} for OS and Figure [3b](#F3){ref-type="fig"} for PFS) although not statistically significant.

![The overall survival (OS, **a**) and progression-free survival (PFS, **b**) according to the level of PD-1 expression among subgroup of patients who did not receive upfront autologous stem-cell transplantation (ASCT).](oncotarget-08-87317-g003){#F3}

Survival of patients with high PD-1 expression {#s2_6}
----------------------------------------------

We further analyzed survival of patients with high PD-1 expression to better characterize the patients with high PD-1 expression in PCNSL tumor microenvironment. The median survival of patients with high PD-1 expression was only 15.8 months (95% CI: 11.7--19.9) for OS and 10.4 months (95% CI: 3.3--17.5) for PFS. However, the median OS of patients with low PD-1 expression was not reached, and median PFS was 24.7 months (95% CI: 9.8--39.5) in patients with low PD-1. All the PCNSL patients with high PD-1 expression had DLBCL histology and two out of six patients showed positive serum EBV DNA among high PD-1 patients. Among six patients with high PD-1 expression, three patients achieved CR1 and five patients achieved CR after completion of primary chemotherapy.

Among these high PD-1 expressing patients, four patients died of disease progression, although four of whom received WBRT consolidation (median 4.0 \[range 30.6--54.0\] Gy) and one patient received upfront ASCT consolidation. Among four patients with high PD-1 who died of progression, two patients were intermediate-risk, one patient was low-risk, and one patient had missing data according to the IELSG scoring. Regarding MSKCC scoring, two patients belonged to low-risk, and the remaining two patients belonged to intermediate and high-risk, respectively. Additional characteristics of patients with high PD-1 expression are provided in Table [5](#T5){ref-type="table"}.

###### Clinical characteristics of six patients with high PD-1 expression

      Age   Gender   ECOG PS   LDH        Lesion     CSF protein   IELSG scoring   MSKCC scoring   PD-1, cells/ HPF   PD-L1, cells/ HPF   PD-L2, cells/ HPF   Initial treatment   Interim response   Final response after primary chemotherapy   Treatment after primary chemotherapy   OS (mon)   PFS (mon)   COD
  --- ----- -------- --------- ---------- ---------- ------------- --------------- --------------- ------------------ ------------------- ------------------- ------------------- ------------------ ------------------------------------------- -------------------------------------- ---------- ----------- ----------
  1   68    F        2         Elevated   Non-deep   Normal        3               2               92                 10                  0                   MVP                 CR1                CR                                          Consolidation WBRT                     15.8       10.4        PD
  2   34    F        1         Normal     Deep       Elevated      2               0               132                10                  110                 MVP                 CR1                CR                                          Upfront ASCT                           8.1        8.1         PD
  3   59    F        1         Normal     Non-deep   Normal        0               1               230                7                   5                   MVD                 Non- CR1           CR                                          Consolidation WBRT                     34.5       15.2        Censored
  4   64    M        1         Normal     Deep       N/A           N/A             1               150                18                  200                 MVD                 Non- CR1           CR                                          Consolidation WBRT                     17.9       17.9        PD
  5   39    M        1         Normal     Deep       Normal        1               0               240                78                  200                 MVD                 Non- CR1           PR                                          Salvage Chemotherapy                   14.5       9.3         PD
  6   60    M        1         Normal     Deep       Elevated      2               1               157                5                   70                  MVD                 CR1                CR                                          Consolidation WBRT                     21.8       16.2        Censored

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; IELSG, International Extranodal Lymphoma Study Group; MSKCC, Memorial Sloan Kettering Cancer Center; HPF, high power field; OS, overall survival; PFS, progression-free survival; COD, cause of death; F, Female; M, Male; DLBCL, diffuse large B-cell lymphoma; N/A, not available; MVP, methotrexate, vincristine, procarbazine and dexamethasone; MVD, methotrexate, vincristine and dexamethasone; CR1, complete response after initial two cycles of chemotherapy; CR, complete response; PR, partial response; ASCT, autologous stem-cell transplantation; WBRT, whole-brain radiotherapy; PD, progressive disease.

Correlation of PD-1 expression with PD-L1 and PD-L2 expression levels {#s2_7}
---------------------------------------------------------------------

The association of PD-1 expression with PD-L1 and PD-L2 expression in tumor microenvironment of PCNSL is shown in Table [6](#T6){ref-type="table"}. The level of PD-1 expression was significantly associated with the level of PD-L1 (*P* = 0.020) and PD-L2 (*P* \< 0.001), respectively (Table [6](#T6){ref-type="table"}).

###### Correlation of PD-1 expression with PD-L1 and PD-L2

  Parameters   Correlation coefficient   *P*
  ------------ ------------------------- ---------
  PD-L1        0.267                     0.020
  PD-L2        0.397                     \<0.001

DISCUSSION {#s3}
==========

In this study, we found that high immunohistochemical PD-1 expression in biopsy specimen of patients with PCNSL at diagnosis was significantly associated with inferior OS and PFS.

Much information has been accumulated regarding the pathogenesis and tumor microenvironment of PCNSL \[[@R13]\]. However, in addition to the rarity of the disease, obtaining adequate numbers of specimens is difficult and thus prognostic roles of studied biomarkers have been unclear. Therefore, IELSG or MSKCC scoring is thus far considered the best available clinical tool for risk-stratifying PCNSL patients \[[@R2], [@R3]\], although biological prognostic markers that also consider the tumor microenvironment and that can be used as a therapeutic target are needed to improve prognostication and survival of patients with PCNSL. Although our group recently reported prognostic importance of CD68 expression in PCNSL microenvironment \[[@R6]\], the major limitation was regarding therapeutic implication as it is difficult to modulate immune response via CD68 positive macrophages in PCNSL tumor microenvironment.

In this regard, PD-1 is an attractive emerging therapeutic target because it has been shown to be expressed in various cancers as well as in hematologic malignancies \[[@R14], [@R15]\]. Regarding PD-1 expression in PCNSL, Berghoff *et al*. \[[@R16]\] were among the first to demonstrate PD-1 and PD-L1 expression in PCNSL. Of 20 PCNSL patient specimens, 2 (10.0%) showed moderate intensity and 1 (5.0%) had high intensity. Besides, Four *et al.* \[[@R17]\] reported expression of high PD-1 (2+) in 6.2% of patients with PCNSL. The proportions of high PD-1 expressing patients are similar to our study, as 7.9% of our patients expressed high PD-1. Compared to those studies, our study recruited more number of patients who were initially homogenously treated with HD-MTX-based chemotherapy. We also performed subgroup analysis according to the upfront ASCT, as the role of upfront ASCT in high-risk patients with PCNSL was emphasized \[[@R18]\].

One of our patient with high PD-1 expression died of progression even after receiving upfront ASCT. Interestingly, the poor prognosis of patients with high PD-1 expression was initially indistinguishable using the IELSG or MSKCC scoring systems; because among four high PD-1 expressing patients who died of disease progression, none of them belonged to the high-risk group according to IELSG scoring and only one of them belonged to the high-risk group regarding MSKCC scoring. However, if we knew that high PD-1 expression predicted poor survival in PCNSL, we would have been able to get more help regarding selection of treatment for these high-risk patients.

There were high expressions of PD-L1 and PD-L2 in 13.2% and 42.1% of our cohort, respectively. Regarding PD-L1 expression, our data also showed quite similar rate to that of Four *et al.* \[[@R17]\], as they reported 18.7% patients were PD-L1 high. However, these rates are relatively low compared to a recent study of PD-L1 expression in glioblastoma, which is a completely different disease but also the malignant case in the CNS \[[@R19]\].

PD-L1 expression might have been induced by genetic aberrations within tumor cells such as Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, which harbor amplification of 9p24.1, a genomic region that encodes PD-L1 and PD-L2. Interestingly, gain of 9p24.1 was also observed in PCNSL \[[@R7]\]. Indeed, PCNSL is associated with immunodeficiency \[[@R1]\], and PCNSL might evade the immune system utilizing PD-1 pathway \[[@R9]\], resulting in poorer outcome compared to non-CNS disease. Our observation suggests a possible link between high PD-1 expression and poor survival, which could explain the more aggressive behavior associated with high PD-1 expression. Furthermore, we demonstrated significant correlation of PD-1 expression with PD-L1 and PD-L2, which is in line with previous studies \[[@R17], [@R20]\]. Therefore, our study might be used as a basis for future clinical trial targeting PD-1 pathway in PCNSL.

We acknowledge our limitation as the expression of PD-1 and PD-L1/PD-L2 have not been defined in specific cell type due to the lack of double staining with CD20, CD3 or other markers for macrophages. However, expression of PD-1 in tumor infiltrating lymphocytes and PD-L1 in tumor cells were distinguished with microscopic visualization by two independent experienced hematopathologists. Therefore, our claim that high PD-1 expression in tumor microenvironment of PCNSL is associated with poor survival is assuming that high PD-1 expression on tumor infiltrating lymphocytes in PCNSL tumor microenvironment is associated with poor survival of patients with PCNSL at diagnosis.

We also estimated PD-1, PD-L1, and PD-L2 expression visually followed by calculation of the mean number of positive cells/HPF and cut-off values have been chosen by AUC of receiver operating characteristic (ROC) curve for analytic purposes. However, we acknowledge the fundamental limitation to standardize the way of determining the optimal cut-off values for PD-1 and its ligands expression from tumor biopsy samples is difficult. Therefore, the predictive relevance of our method and determining optimal cut-off values remain to be validated in future studies.

In conclusion, we showed that high PD-1 expression in PCNSL tumor microenvironment is significantly associated with inferior survival. Better knowledge of the PD-1 pathway in PCNSL, along with future trials that include PD-1 based biological risk-stratification and therapeutic targeting, are necessary for this challenging disease.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Seventy-six biopsy-proven PCNSL patients between December 2004 and March 2016 at Severance Hospital, South Korea for whom archived formalin-fixed and paraffin-embedded (FFPE) tissue blocks at initial diagnosis were available were retrospectively analyzed. The patient cohort was previously described \[[@R6]\]. All the patients included in this study were immunocompetent and did not have a history of immunosuppressive drug use nor malignancies other than PCNSL. We excluded human immunodeficiency virus-related PCNSL. The diagnosis was made histologically by surgical resection or stereotactic brain biopsy. All the patients received HD-MTX-based chemotherapy as an initial treatment homogenously without receiving steroid treatment before pathologic confirm.

PCNSL was stipulated as histologically confirmed NHL confined to the CNS \[[@R1]\]. Baseline clinical data were retrospectively collected including age, gender, IELSG prognostic score, MSKCC prognostic score, serum EBV positivity by quantitative polymerase chain reaction, serum human immunodeficiency virus positivity by enzyme immunoassay, type of treatment including consolidative upfront ASCT and WBRT, initial response to treatment, and survival.

The ECOG performance status was determined at the time of diagnosis. Pre-treatment evaluation included contrast enhanced magnetic resonance imaging of the brain, positron emission tomography-computed tomography to exclude systemic NHL, bone marrow aspiration and biopsy with histologic, cytologic, and immunocytologic examination, ocular examination including a slit lamp examination to distinguish ocular involvement, and lumbar puncture for cerebrospinal fluid (CSF) analysis, unless contraindicated. Elevated CSF protein concentration was defined as a level more than 45 mg/dL in patients younger than 60 years of age, and a level more than 60 mg/dL in patients older than 60 years of age \[[@R2]\]. Involvement of deep brain structures was defined as involvement of the periventricular regions, basal ganglia, brainstem, and cerebellum.

The IELSG scoring system \[[@R2]\], which consists of five prognostic factors that are associated with poor survival in PCNSL including age \> 60 years, ECOG performance status \> 1, elevated serum lactate dehydrogenase level, elevated CSF protein concentration, and involvement of deep brain structures, was assessed in 66 (86.8%) patients, as data regarding the CSF protein level were not available in 10 (13.2%) patients. The MSKCC scoring system \[[@R3]\], consisting of age ≥ 50 and Karnofsky performance score (KPS) ≥ 70, which are predictors of poor outcome in PCNSL, was evaluated in all patients.

All patients included in this study had received HD-MTX-based chemotherapy as an initial treatment, such as HD-MTX, vincristine, and dexamethasone (MVD, *n* = 41) or HD-MTX, procarbazine, and dexamethasone (MVP, *n* = 35). The MVD regimen consisted of HD-MTX 3.5 g/m^2^ D1 delivered intravenously (i.v.) with leucovorin rescue (15 mg every 6 hours, minimum 12 doses), started 24 hours after the MTX infusion, vincristine 1.4 mg/m^2^ (maximum 2 mg i.v.) D1, and dexamethasone 20 mg i.v. D1-5. The MVP regimen consisted of HD-MTX 3.0 g/m^2^ D1 i.v. with leucovorin rescue (15 mg every 6 hours, minimum 12 doses), started 24 hours after the MTX infusion, vincristine 1.4 mg/m^2^ (maximum 2 mg i.v.) D1, procarbazine 100 mg/m^2^ D1-14 given orally, and dexamethasone 20 mg i.v. D1-14. Tumor response was assessed according to the criteria of the International PCNSL Collaborative Group \[[@R21]\]. Treatment response was recorded as complete response1 (CR1), if the patients achieved a CR (disappearance of all enhancing abnormalities on brain magnetic resonance imaging) after initial induction HD-MTX-based chemotherapy. The institutional review board of Severance Hospital approved this study.

Immunohistochemistry of PD-1, PD-L1, and PD-L2 {#s4_2}
----------------------------------------------

Immunohistochemical staining for PD-1 (clone NAT105; dilution 1:100; Abcam, Cambridge, UK), PD-L1 (clone ab58810; dilution 1:100; Abcam, Cambridge, UK), and PD-L2 (clone MIH18; dilution 1:50; Sigma-Aldrich, St. Louis, MO, USA) using archived FFPE tissue slides were performed according to the protocols for automated immunohistochemistry using the Ventana Discovery XT automatic platform (Ventana Automated Systems, Tucson, AZ, USA).

Quantitative assessment of PD-1, PD-L1, and PD-L2 {#s4_3}
-------------------------------------------------

The stained sections were screened at 40× magnification via Olympus BX51 microscope (Olympus, Deutschland GmbH, Hamburg, Germany; 40× objective, 10× ocular, and 0.55 mm ocular diameter) to identify the areas with the most abundant positive cells within the tumor area. Six representative fields with the highest staining tumor cells were selected at a magnification of 400× HPF. We analyzed 1.44 mm^2^ per case because the area of a single image was 0.24 mm^2^. PD-1 positive tumor-infiltrating mononuclear cells (i.e. lymphocytes and macrophages) and PD-L1/PD-L2 positive tumor cells were counted manually, and the mean numbers of positive cells/HPF were calculated. Blinded quantitative assessments were performed by two independent pathologists (SHK and W-IY). The cut-off values for high PD-1, PD-L1, and PD-L2 were evaluated by the AUC of the ROC curve, and we established cut-offs of 70 cells/HPF for PD-1 and 100 cells/HPF for PD-L1/PD-L2. Therefore, high PD-1 expression was defined as ≥ 70 cells/HPF, and high PD-L1/PD-L2 were defined as ≥ 100 cells/HPF.

Statistical analysis {#s4_4}
--------------------

OS was defined as the time from initial diagnosis to death or last follow-up; PFS was defined as the time from initial diagnosis to relapse, disease progression, or death. Patient data were collected retrospectively until March 2016, and patients who were alive at the last follow-up contact were censored. OS and PFS were plotted using the Kaplan-Meier method and compared using the log-rank test. Analysis of categorical variables was performed using the chi-squared test or Fisher\'s exact test. The Wilcoxon rank-sum test was used for continuous variables. The Cox regression model was used in both univariate and multivariate analysis. All *P* values were two-sided, and *P* \< 0.05 was considered statistically significant. Statistical analyses were performed using SPSS for Windows (Version 20.0, IBM Corp., Chicago, IL, USA).

This work was presented in the form of e-poster presentation at the 21th Congress of the European Hematology Association, Copenhagen, Denmark, June 9-12, 2016.
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